Basma Radwan's questions to Xenon Pharmaceuticals Inc (XENE) leadership • Q2 2025
Question
Basma Radwan from Leerink Partners inquired about the clinical differences between Type I and Type II bipolar depression, whether Ezetucalner is expected to have differential efficacy, and if mania is being assessed as an endpoint in the trial.
Answer
Chief Medical Officer Christopher Kenney explained that Type I involves manic episodes while Type II involves hypomania, and the trial includes both populations with stratification to ensure balance. He stated that while they expect efficacy in both, it is unknown. Mania is being monitored as a safety outcome to ensure the drug does not exacerbate the condition, rather than as an efficacy endpoint.